BOLD — Boundless Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1782303 ·
Last close
$2.41
Market Cap
$56.90M
52W High
$3.16
52W Low
$0.96
ADV30
140,905
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -6,201,000 | -5,364,000 | 63,594,000 | 34,909,000 | 1,872,000 |
| Jun 2026 | 0 | — | -24,384,000 | -23,693,000 | 73,744,000 | 20,213,000 | 7,768,000 |
| Mar 2026 | 0 | — | -14,475,000 | -13,555,000 | 140,970,000 | 17,483,000 | 54,587,000 |
| Dec 2025 | 0 | — | -14,002,000 | -12,885,000 | 157,059,000 | 17,868,000 | 58,405,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,934,000
Investing CF
$75,393,000
Financing CF
$954,000
CapEx
$-485,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.47
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-302,281,000
Inventory
—
Receivables
—
ST Investments
$27,985,000
EBIT TTM
$-59,062,000
Pretax Income TTM
$-55,497,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -63,552,000 | -58,197,000 | 157,059,000 | 58,405,000 | 98,654,000 | -46,661,000 |
| Dec 2024 | 0 | -73,267,000 | -65,363,000 | 206,409,000 | 55,767,000 | 150,642,000 | -60,841,000 |
| Dec 2023 | 0 | -54,796,000 | -49,434,000 | 129,894,000 | 256,976,000 | -127,082,000 | -46,855,000 |
| Dec 2022 | 0 | -46,469,000 | -45,901,000 | 76,829,000 | 158,525,000 | -81,696,000 | -39,596,000 |
TTM Snapshot
Revenues TTM
$3,996,000
NetIncome TTM
$-64,012,000
OpCashFlow TTM
—
Assets (Latest)
$73,744,000
Forward EPS
$-0.75
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp. | $57.13M | $2.94 | — |
| CTOR | CITIUS ONCOLOGY, INC. | $57.91M | $0.55 | — |
| QUCY | Quantum Cyber N.V. | $54.38M | $0.62 | — |
| XBIT | XBiotech Inc. | $54.27M | $1.78 | — |
| INCR | Intercure Ltd. | $54.16M | $3.61 | — |
News headlines (Yahoo Finance, 1h cache)
Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
2026-09-28 12:00 · Yahoo
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
2026-06-23 11:30 · Yahoo
Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today
2026-06-24 02:53 · Yahoo
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
2026-04-17 20:49 · Yahoo
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-08 11:00 · Yahoo
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
2026-09-09 12:00 · Yahoo
BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History
2026-06-23 17:32 · Yahoo
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
2026-03-17 20:52 · Yahoo
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-03-09 11:00 · Yahoo
Boundless Bio to Participate in the Leerink Global Healthcare Conference
2026-03-04 12:00 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-11-17 17:18:09 | 2026-11-13 | Tang Kevin | 10% | P - Purchase | 2.4 | 13812 | 33149 |